Anupam Rasayan is a custom synthesis manufacturer that develops and produces complex specialty chemicals and advanced intermediates for global companies in the agrochemical, pharmaceutical, and performance materials sectors.
The company possesses a narrow moat based on high switching costs and technical expertise required for multi-step chemical synthesis, evidenced by long-term contracts (5-10 years) with global innovators. However, the moat is weakened by mediocre returns on capital (10.3% ROCE) and a lack of pricing power, as margins have remained flat or slightly declined despite claims of high-value chemistry.
Management has been aggressive in reinvesting for growth, completing a massive ₹6,700 million capex cycle and acquiring Tanfac and Jayhawk to expand geographically and vertically. While these moves have scaled the business, the low EPS CAGR (2.6%) relative to revenue growth (15.8%) suggests that capital intensity is high and value creation for shareholders has been diluted by frequent equity raises.
The company's aggressive expansion strategy collapsed under the weight of its own capital intensity. Despite scaling revenue through expensive acquisitions and massive capex, the business failed to translate top-line growth into bottom-line earnings, as evidenced by the historical 2.6% EPS CAGR. The high working capital requirements and poor cash conversion eventually led to a liquidity crunch when interest rates rose, while the frequent equity dilutions used to fund growth permanently impaired shareholder value. The specialized chemistry moat proved to be a mirage, as the company lacked the pricing power to pass on rising costs, resulting in stagnant returns on capital that never exceeded the cost of capital.
RichFakir rates Anupam Rasayan India Ltd's business quality as poor — 38/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Anupam Rasayan India Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Anupam Rasayan India Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Anupam Rasayan India Ltd's fair value is about ₹207 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →